SCHEMBL2498477

SCHEMBL2498477

NC(=O)c1ccc(Cl)c(C(=O)Nc2cnc(Nc3ccc(S(=O)(=O)C4CCNCC4)cc3)nc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 3/20 0.46
▸ SRC P12931 2/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ KDR P35968 2/20 0.43
▸ YES1 P07947 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ POLB P06746 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LCK P06239 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ NAMPT P43490 3/20 0.40
▸ IKBKB O14920 1/20 0.39
▸ CHUK O15111 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SYK P43405 3/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498483 0.90 BTK (0.51) BTKSRCABL1KDRYES1
SCHEMBL14304344 0.89 BTK (0.54) BTKSRCABL1KDRYES1
SCHEMBL2498581 0.88 BTK (0.47) BTKSRCABL1KDRYES1
SCHEMBL2495433 0.86 BTK (0.47) BTKSRCABL1KDRYES1
SCHEMBL2497569 0.86 BTK (0.54) BTKPDGFRBLCKMAPK14JAK2
SCHEMBL2497204 0.85 BTK (0.46) BTKSRCABL1KDRYES1
SCHEMBL12190173 0.85 BTK (0.46) BTKSRCABL1KDRYES1
SCHEMBL2497186 0.83 BTK (0.68) BTKSRCABL1KDRPDGFRB
SCHEMBL12190172 0.83 BTK (0.45) BTKSRCABL1KDRYES1
SCHEMBL12212900 0.82 BTK (0.43) BTKSRCABL1KDRYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885SRC 5/4885ABL1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback